Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights
November 07, 2018 16:10 ET
|
Voyager Therapeutics, Inc.
One-time treatment with VY-AADC demonstrates durable improvements in motor function at 18 months and beyond from ongoing Phase 1b trial Recent preclinical results for Huntington’s disease and...
Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
November 07, 2018 16:10 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
International Stem Cell Corporation Announces Positive Top-Line Preliminary Results from Parkinson’s Disease Clinical Trial
November 05, 2018 08:30 ET
|
International Stem Cell Corporation
CARLSBAD, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based...
Global Kinetics Corporation’s PKG® Smartwatch Provides Clinically Meaningful Improvement in Parkinson’s Disease Symptom Assessment, Management and Medication Optimization, As Well As Projected Per Patient Cost Savings
November 02, 2018 09:00 ET
|
Global Kinetics Corporation
Data Recently Presented at the 2018 International Congress of Parkinson’s Disease and Movement Disorders PORTSMOUTH, N.H., LONDON and MELBOURNE, Australia, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Global...
Enable Me Announces Vintage MOTOmed Viva 2 Video Contest in celebration of National Physical Therapy Month; The Most Creative Video About the Classic Viva 2 Wins A New MOTOmed Muvi
October 17, 2018 13:03 ET
|
Enable Me
TAMPA, Fla., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Thousands of users of the MOTOmed Viva 2 movement therapy device, first introduced more than a decade ago, have a chance to win an upgrade to the new,...
International Stem Cell Corporation Doses Tenth Patient in Parkinson's Disease Clinical Trial
October 08, 2018 08:30 ET
|
International Stem Cell Corporation
CARLSBAD, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage...
Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease
October 04, 2018 09:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous...
Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
October 03, 2018 07:30 ET
|
Biogen Inc.
CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Data to be presented from the BIIB092 program for progressive supranuclear palsy and BIIB054 program for Parkinson’s disease highlight Biogen’s...
Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights
August 07, 2018 16:07 ET
|
Voyager Therapeutics, Inc.
Clinical data updates and regulatory feedback for VY-AADC during the quarter support planned pivotal program for Parkinson’s disease Pipeline programs progressing with updated preclinical data from...
Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update
July 17, 2018 07:04 ET
|
Voyager Therapeutics, Inc.
Voyager continues to plan to submit a BLA for VY-AADC based on its pivotal program and Type C meeting feedback Positive interim results with VY-AADC from the Phase 1 posterior trajectory trial...